using mrd status to guide treatment for relapsed/refractory multiple myeloma
Published 4 years ago • 66 plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
1:01:42
using mrd status as an endpoint for drug approval with dr. manni mohyuddin
-
2:55
using mrd to guide treatment decisions during sct in multiple myeloma
-
3:01
the benefit of using mrd to guide treatment decisions in multiple myeloma
-
9:50
treatment for relapsed and refractory multiple myeloma
-
2:03
the increasing use of mrd to personalize therapy for multiple myeloma in clinical practice
-
3:22
the challenges of treating r/r myeloma
-
3:05
individualizing treatments in multiple myeloma
-
1:11:05
the utility of mrd testing for myeloma patient treatment and outcomes
-
5:15
mrd assessment of response to myeloma therapy
-
1:33:39
the relevance of mrd assessment in the clinical management of multiple myeloma (mm) patients
-
1:38
dr. raje on treatment approaches for relapsed/refractory myeloma
-
1:05
are we ready for mrd-guided therapy in multiple myeloma?
-
23:32
approaching mrd in multiple myeloma
-
1:27
using mrd to guide treatment decisions in the clinic
-
4:30
triplet regimens for relapsed multiple myeloma
-
51:36
relapsed refractory multiple myeloma | current treatment options | options on the horizon
-
3:43
mrd-guided treatment cessation in multiple myeloma
-
1:12:05
a practical approach to mrd: testing with clonoseq
-
1:02:37
should mrd status be used as a good endpoint for drug approval?